Navigation Links
Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Date:8/16/2012

THE WOODLANDS, Texas, Aug. 16, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

The Phase 1 study of LX2931, an inhibitor of sphingosine-1-phosphate lyase, was a dose-ranging study to explore higher doses of LX2931 in patients with rheumatoid arthritis. The study involved 10 patients with rheumatoid arthritis, eight of whom were randomized to LX2931 and two to placebo.  The primary endpoint in the study was an evaluation of the safety and tolerability of escalating doses of LX2931 compared with placebo over 12 weeks in subjects with active rheumatoid arthritis.  Secondary endpoints included pharmacokinetic and disease activity measures. 

Patients in the study received increasing doses over the course of the study, beginning at 50 mg QD and escalating to 500 mg QD.  LX2931 was well-tolerated at all doses evaluated, with no serious adverse events and no withdrawals due to adverse events. Seven of eight patients on LX2931 achieved drug trough levels greater than 60 ng/ml, a pharmacokinetic measure which a post-hoc analysis of data from a prior Phase 2 study of LX2931 had suggested was associated with better responses in American College of Rheumatology (ACR) measures in the study.  Six of the eight LX2931-treated patients experienced a drop from baseline in the DAS28 score of greater than or equal to 1.2, as did both placebo patients.  ACR20 and ACR50 responses were achieved at varying frequencies in both LX2931-treated and placebo patients, but two of eight patients dosed with LX2931 achieved an ACR70 response during the course of the study,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
3. Lexicon to Provide Second Quarter 2012 Financial Results
4. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
5. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
6. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
7. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
8. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
10. Lexicon to Provide First Quarter 2012 Financial Results
11. Nouveau Life Pharmaceuticals (NOUV) Releases Calcium & Vitamin D for Strong Bones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
(Date:9/19/2014)... cancers have abnormally upregulated chemical signals related to ... during tumor formation is not fully understood. , ... both researchers in the department of Pathology and ... University of Pennsylvania, and colleagues report that TIPE3, ... targeting these pathways. , Lipid second messengers play ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 According to ... of the embattled blood-thinner Xarelto, named as defendants in ... Common Pleas, have moved the court to dismiss those ... not have sufficient connection with Philadelphia.* The cases include, ... al. (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... 19, 2014 The Alliance for ... with the National Fire Protection Association (NFPA), a ... formalized today in a Memorandum of Understanding signed ... workers and other stakeholders with information, guidance and ... the health and safety of workers in ready-made ...
Breaking Medicine News(10 mins):Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:New cancer drug target involving lipid chemical messengers 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3
... , FRIDAY, Aug. 12 (HealthDay News) -- Religious ... facing hardship or conflict, a new study indicates. ... such link. Not only are fewer people religious ... in regions where there,s hardship and strife, regardless of ...
... HealthDay Reporter , THURSDAY, Aug. 11 (HealthDay News) -- Depressed ... suggests. "We know that stroke can increase risk of ... said study author An Pan, a research scientist at the ... associated with hormonal changes in the body and affects chemicals ...
... (HealthDay News) -- Obstructive sleep apnea (OSA) and sleepiness rapidly ... machines, a new study finds. CPAP is a common ... during sleep due to the repeated blockage of the upper ... stream of air through a mask or nose piece the ...
... of continuous positive airway pressure machines (CPAP) for patients ... the therapy is withdrawn, according to Swiss research. ... the American Thoracic Society,s American Journal of Respiratory ... obstructive sleep apnea who are established on CPAP treatment, ...
... in illness and recovery is a primary influence upon ... a first-of-its-kind study has discovered. Outreach and education efforts ... concerns and improve health care quality in this rapidly ... fasting occurring this month is but one of many ...
... Researchers from the Indiana University have identified common ... in Intensive Care Units (ICUs). The study, published ... and Hospital Epidemiology , the journal of the ... lessons learned from six ICUs as they implemented ...
Cached Medicine News:Health News:Religion Might Boost Happiness in Times of Stress 2Health News:Depressed Women Could Face Raised Risk of Stroke 2Health News:Depressed Women Could Face Raised Risk of Stroke 3Health News:Withdrawal of CPAP therapy results in rapid recurrence of OSA 2Health News:Religious beliefs shape health care attitudes among US Muslims 2Health News:Religious beliefs shape health care attitudes among US Muslims 3Health News:Common themes emerge in hospitals' anti-MRSA efforts: Study 2
... is a mechanical catheter intended to percutaneously ... access grafts. The disposable catheter requires no ... spiral shaft which extends beyond the 6F ... tip. In use, the tip spins to ...
... HYDROLYSER Percutaneous Thrombectomy Catheter is ... for rapid, effective and easy removal ... shunts. The HYDROLYSER catheter provides an ... thrombolytic therapy. ,Compatible with ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
... The AVX catheter is designed to ... 12mm. High-pressure saline jets travel backwards ... to create a low pressure zone ... drawn into the catheter where it ...
Medicine Products: